Pipeline — registered trials by phase
An Observational Post-Marketing Safety Registry of Sativex®
— · Multiple Sclerosis, Diabetes, Cancer · Completed · est. 2015-01
Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY
— · Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex · Active Not Recruiting · est. 2027-02
Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy
— · Maternal Complications, Pregnancy Complication, Birth Outcomes, Adverse · Recruiting · est. 2033-08-31
CPX-351 Real-World Effectiveness and Safety Study
— · Acute Myeloid Leukemia · Completed · est. 2022-06-15
A Post-Marketing Observational Study of VYXEOS™
— · Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Therapy-Related Acute Myeloid Leukemia · Completed · est. 2019-10-26
To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
— · Extensive-stage Small-cell Lung Cancer · Completed · est. 2025-06-04
A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
— · Tuberous Sclerosis Complex Associated Neuropsychiatric Disease · Completed · est. 2026-04-06
Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting
— · Seizures · Active Not Recruiting · est. 2026-07
Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients
— · Obstructive Sleep Apnea Syndrome · Completed · est. 2005-06
Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogenic Hematopoietic Cell Transplant Recipients
— · Adenovirus Infections, Human · Completed · est. 2015-09
A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy
— · Narcolepsy · Completed · est. 2021-08-09
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
— · Advanced Cancer, Metastatic Cancer, Solid Tumor · Active Not Recruiting · est. 2028-04-01
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
— · HER2-expressing Cancers · Completed · est. 2024-10-31
Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients
— · Hepatic Impairment · Completed · est. 2014-05
Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex
— · Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor · Completed · est. 2008-03
Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects
— · Hepatic Impairment · Completed · est. 2011-09
A Study of the Safety and Tolerability of GWP42006 in Healthy Subjects
— · Epilepsy · Completed · est. 2013-12
An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience.
— · Healthy Subjects · Completed · est. 2015-02
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
— · Focal Seizures · Recruiting · est. 2027-11-29
A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia
— · Acute Myeloid Leukemia · Completed · est. 2022-02-07
Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
— · Acute Myeloid Leukemia · Completed · est. 2015-04
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female Participants
— · Healthy Participants · Not Yet Recruiting · est. 2027-02-27
Sativex Thorough QT/QTc Study
— · Effects of Sativex on ECG · Completed · est. 2008-06
A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)
— · Epilepsy, Dravet Syndrome · Completed · est. 2015-03-09
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
— · Acute Myeloid Leukemia · Completed · est. 2011-12
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
— · Advanced Pheochromocytoma and Paraganglioma, PCPG · Recruiting · est. 2028-12-15
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
— · Meningioma · Recruiting · est. 2028-10-25
Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor
— · Essential Tremor · Completed · est. 2008-08
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
— · Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma · Completed · est. 2013-08
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
— · Breast Cancer, Gastric Cancer, Esophageal Cancer · Recruiting · est. 2026-12-31
An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy
— · Epilepsy · Completed · est. 2019-05-27
A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
— · Cancer · Completed · est. 2015-01
An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)
— · Graft-versus-host Disease, Acute-graft-versus-host Disease · Completed · est. 2020-05-12
A Phase 2 RCT Study of CX-8998 for Essential Tremor
— · Essential Tremor · Completed · est. 2018-07-16
CMX001 in Post-transplant Patients With BK Virus Viruria
— · Viruria · Completed · est. 2010-10
GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes
— · Dyslipidemias, Diabetes Mellitus, Type 2 · Completed · est. 2012-05
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
— · HER2-positive Breast Cancer, Breast Cancer · Recruiting · est. 2028-01-01
Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer
— · Colorectal Neoplasms · Completed · est. 2008-12
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
— · Acute Myeloid Leukemia · Completed · est. 2010-06
A Study of GWP42006 in People With Focal Seizures - Part B
— · Epilepsy, Focal Seizures · Completed · est. 2017-07
Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
— · Cytomegalovirus Infection · Completed · est. 2012-01
A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder
— · Schizophrenia, Schizophrenia-related Psychotic Disorder · Completed · est. 2015-01-08
A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
— · Narcolepsy With Cataplexy · Completed · est. 2019-01-24
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
— · Metastatic HER2-positive Breast Cancer · Recruiting · est. 2028-04-28
Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses
— · Double-stranded DNA Virus · Completed · est. 2012-12
A Study of the Long-term Safety of Sativex Use
— · Multiple Sclerosis, Spasticity, Pain · Completed · est. 2004-12
An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
— · Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia · Completed · est. 2022-07-13
Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis
— · Spasticity, Multiple Sclerosis · Completed · est. 2009-01
An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients
— · Multiple Sclerosis · Completed · est. 2002-07
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
— · Tuberous Sclerosis Complex, Seizures · Completed · est. 2021-06-11
Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy
— · Narcolepsy · Completed · est. 2007-09
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
— · Severe Hepatic Veno-Occlusive Disease · Completed · est. 2008-09
A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain
— · Pain, Peripheral Neuropathy · Completed · est. 2007-07
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
— · Pain, Advanced Cancer · Completed · est. 2016-01-27
A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy
— · Palliative Care, Pain, Cancer · Completed · est. 2004-02
A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis
— · Multiple Sclerosis, Neuropathic Pain · Completed · est. 2002-08
GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
— · Epilepsy, Dravet Syndrome · Completed · est. 2018-04-09
Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia
— · Fibromyalgia · Completed · est. 2010-07
A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy
— · Juvenile Myoclonic Epilepsy · Recruiting · est. 2028-08-01
A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.
— · Pain, Peripheral Neuropathy · Completed · est. 2004-03
A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.
— · Pain, Peripheral Neuropathy · Completed · est. 2007-06
Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection
— · Adenovirus Infection · Completed · est. 2016-06
A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia
— · Pain, Peripheral Neuropathy · Completed · est. 2006-10
A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury
— · Pain · Completed · est. 2005-01
A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH
— · Narcolepsy, Idiopathic Hypersomnia · Recruiting · est. 2027-12-23
A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.
— · Fibromyalgia · Completed · est. 2009-04
Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain
— · Pain, Cancer · Completed · est. 2006-09
LuvoxFluvoxamine Maleate
XywavCalcium Oxybate
ZepzelcaLurbinectedin
Source: ClinicalTrials.gov (trials where Jazz Pharmaceuticals is lead sponsor; 73 active or completed) and Drugs@FDA (3 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-10-09Current report (material event)
- 8-K2026-09-23Current report (material event)
- 8-K2026-09-15Current report (material event)
- 8-K2026-08-31Current report (material event)
- 8-K2026-08-25Current report (material event)
- 8-K2026-08-10Current report (material event)
- 8-K2026-08-10Current report (material event)
- SCHEDULE 13G2026-08-06SCHEDULE 13G
- 10-Q2026-08-03Quarterly report
- 8-K2026-08-03Current report (material event)
- 8-K2026-07-24Current report (material event)
- DEFA14A2026-07-14DEFA14A
- ARS2026-06-08Annual report to holders
- DEFA14A2026-06-08DEFA14A
- DEF 14A2026-06-08Proxy statement
- PRE 14A2026-05-29PRE 14A
- 8-K2026-05-29Current report (material event)
- 10-Q2026-05-05Quarterly report
- 8-K2026-05-05Current report (material event)
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- 10-K/A2026-04-24Annual report (amended)
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- 10-K2026-02-24Annual report
- 8-K2026-02-24Current report (material event)
- 8-K2026-01-12Current report (material event)
- 8-K2025-11-17Current report (material event)
- 10-Q2025-11-05Quarterly report
- 8-K2025-11-05Current report (material event)
- 8-K2025-10-28Current report (material event)
- 8-K2025-10-22Current report (material event)
- UPLOAD2025-08-08UPLOAD
- 10-Q2025-08-06Quarterly report
- 8-K2025-08-05Current report (material event)
- CORRESP2025-07-29CORRESP
- 8-K2025-07-25Current report (material event)
- UPLOAD2025-07-17UPLOAD
- DEFA14A2025-07-14DEFA14A
- DEFA14A2025-07-10DEFA14A
- 8-K2025-07-10Current report (material event)
- ARS2025-06-06Annual report to holders
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.